Compare CCTG & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCTG | IMNN |
|---|---|---|
| Founded | 1993 | 1982 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 9.1M |
| IPO Year | 2022 | 2000 |
| Metric | CCTG | IMNN |
|---|---|---|
| Price | $0.61 | $1.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 97.5K | 43.0K |
| Earning Date | 12-23-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $1.47 |
| 52 Week High | $5.64 | $5.85 |
| Indicator | CCTG | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 35.49 |
| Support Level | $0.38 | N/A |
| Resistance Level | $0.65 | $2.18 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 15.47 | 26.03 |
CCSC Technology International Holdings Ltd, through its direct wholly-owned subsidiaries, is principally engaged in the manufacturing and sale of interconnect products, including connectors, cables and wire harnesses. The company produces both original equipment manufacturer (OEM) and original design manufacturer (ODM) interconnect products for manufacturing companies that produce end products, as well as for electronic manufacturing services (EMS) companies. The majority of the company's revenue is derived from the sale of Cable and wire harnesses, and Connectors. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas, Asia, and Others.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.